Progression-free survival, also known as PFS serves to the describe how long a disease (usually cancer) no worse get while the patient to a drug is; It is also for the measurement after the medication is stopped.
T-DM1 used known as Trastuzumab-DM1. Trastuzumab was developed by Genentech, is one of the pharmaceutical giant Roche.
Roche says that information be provided on their findings for presentation at a future Conference. In the last year has been the encouraging results in tumor issued favorable preliminary data on T-DM1, shrinkage in patients with a minimum of 4 months of follow up, but without information on progression-free survival. Side effects were much less compared to conventional chemotherapy.
Daniel Junius, President and CEO of ImmunoGen, said:
"This top-line information about T-DM1 performance in the first row setting is very encouraging and adds the low efficacy and safety data reported a number of T-DM1 studies." We look forward to the detailed data learn, when they at a medical Conference. "be reported"about T-DM1 (trastuzumab Emtansine) Trastuzumab Emtansine Imunogen Hahn's uses (targeted antibodies payload) technology together with the antibody Trastuzumab. This is a global development cooperation agreement between Roche (Genentech) and ImmunoGen.
It experienced phase III studies for second-line and first-line treatment of HER2 positive metastatic breast cancer. A phase II study comparative safety of T-DM1 began in the year 2010.
HAL Barron, m.d., Chief Medical Officer and head of global development, Roche, said:
"These encouraging results support our ongoing development programme for Trastuzumab Emtansine (T-DM1) in first-line HER2-positive metastatic breast cancer." "Trastuzumab Emtansine (T-DM1) is a new treatment with the potential to improve the results for patients with HER2 positive breast cancer due to its efficacy and favourable safety profile."
Breast cancer is the female cancer worldwide. There are approximately 1.4 million new breast cancer diagnoses each year worldwide. More than 450,000 people with breast cancer each year die of the disease.
Between 15% and 25% of women with breast cancer, you have the HER2 positive Typ.Quellen: Roche, ImmunoGen
Written by Christian Nordqvist
See drug information on Herceptin.
Copyright: Medical news today
Not without the permission of medical news today be played
Posts
0 comments: on "T-DM1 offers better breast cancer progression-free survival as only Herceptin and chemotherapy"
Post a Comment